[1] van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci,2008,1137:18-26.
[2] Han DSC, Ni M, Chan RWY, et al. The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet,2020,106:202-214.
[3] Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res,1977,37:646-550.
[4] Chan KC, Jiang P, Sun K, et al. Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. Proc Natl Acad Sci U S A,2016,113:E8159-E8168.
[5] Yu SCY, Jiang P, Peng W, et al. Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. Proc Natl Acad Sci U S A, 2021,118.
[6] Jiang P, Xie T, Ding SC, et al. Detection and characterization of jagged ends of double-stranded DNA in plasma. Genome Res,2020,30:1144-1153.
[7] Ding SC, Lo YMD. Cell-Free DNA Fragmentomics in Liquid Biopsy. Diagnostics (Basel), 2022,12:978..
[8] Lyu X, Tsui YM, Ho DW, et al. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol, 2022,13:1611-1624.
[9] Jiang P, Sun K, Tong YK, et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc Natl Acad Sci U S A,2018,115:E10925-E10933.
[10] Zhang X, Wang Z, Tang W, et al. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology, 2022,76:317-329.
[11] Levitsky J, Kandpal M, Guo K, et al. Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients. Am J Transplant,2022,22:532-540.
[12] Fernandez-Galan E, Badenas C, Fondevila C, et al. Monitoring of Donor-Derived Cell-Free DNA by Short Tandem Repeats: Concentration of Total Cell-Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation. Liver Transpl, 2022,28:257-268.
[13] Baumann AK, Beck J, Kirchner T, et al. Elevated fractional donor-derived cell-free DNA during subclinical graft injury after liver transplantation. Liver Transpl,2022.
[14] Karlas T, Weise L, Kuhn S, et al. Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. J Transl Med 2017;15:106.
[15] Chrysavgis L, Papatheodoridi A, Cholongitas E, et al. Significance of Circulating Cell-Free DNA Species in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22.
[16] Blasi A, Patel VC, Adelmeijer J, et al. Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. JHEP Rep 2019;1:179-187.
[17] Laurent D, Semple F, Starkey Lewis PJ, et al. Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose. BMC Med Genomics 2020;13:60.
[18] Sadeh R, Sharkia I, Fialkoff G, et al. ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. Nat Biotechnol 2021;39:586-598.
[19] Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 2018;379:1754-1765.
[20] Martignano F. Cell-Free DNA: An Overview of Sample Types and Isolation Procedures. Methods Mol Biol 2019;1909:13-27. |
